Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367540 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2SCN8ASCN10A | |
| SCHEMBL16042596 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2SCN8ASCN10A | |
| SCHEMBL30114837 | 0.92 | PTGER4 (0.85) | PTGER4PTGER2 | |
| SCHEMBL691367 | 0.92 | PTGER4 (0.85) | PTGER4PTGER2 | |
| SCHEMBL30114774 | 0.91 | PTGER4 (0.83) | PTGER4PTGER2 | |
| SCHEMBL4448759 | 0.91 | PTGER4 (0.83) | PTGER4PTGER2SCN8ASCN10A | |
| SCHEMBL691300 | 0.91 | PTGER4 (0.83) | PTGER4PTGER2 | |
| SCHEMBL30114822 | 0.90 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL27666415 | 0.90 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL2353288 | 0.90 | PTGER4 (0.81) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697317-A | Use of EP4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia | 株式会社AskAt | 2023-02-03 | — | — | CN | claimed |
| CN-108289960-B | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer | 株式会社AskAt | 2021-07-09 | — | — | CN | claimed |
| US-10342785-B2 | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer | ASKAT INC. (JP) | 2019-07-09 | — | — | US | claimed |
| EP-3344296-B1 | USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER | ASKAT INC (JP) | 2019-05-15 | — | — | EP | claimed |
| EP-2965756-B1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC (JP) | 2018-10-10 | — | — | EP | claimed |
| EP-3344296-A1 | USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER | AskAt Inc. (JP) | 2018-07-11 | — | — | EP | claimed |
| US-20180125832-A1 | USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER | ASKAT INC. (JP) | 2018-05-10 | — | — | US | claimed |
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2017-09-07 | — | — | US | claimed |
| US-9688674-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2017-06-27 | — | — | US | claimed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | claimed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | claimed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | claimed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | claimed |
| CN-1946391-A | Combinations comprising alpha-2-delta ligands | PFIZER PROD INC (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | claimed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | claimed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | claimed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885SCN8A 2191/4885 |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885SCN8A 2245/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | PTGER4 13/4885PTGER2 11/4885SCN8A 2723/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | PTGER4 1/4885PTGER2 2/4885SCN8A 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.